Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Oligosaccharides, particularly those classified as prebiotics (such as fructooligosaccharides and galactooligosaccharides), have garnered scientific interest in the context of autoimmune disorders due to their impact on gut microbiota composition and, consequently, immune system modulation. Preclinical and some early clinical studies suggest that oligosaccharides can promote the growth of beneficial gut bacteria (e.g., Bifidobacteria and Lactobacilli), which in turn may enhance intestinal barrier function and modulate inflammatory responses. Since dysbiosis (microbial imbalance) and increased gut permeability are implicated in the pathogenesis of various autoimmune diseases (such as type 1 diabetes, multiple sclerosis, and rheumatoid arthritis), supporting a healthy microbiome is hypothesized to have therapeutic potential.

However, direct clinical evidence supporting the use of oligosaccharides specifically for the treatment or management of autoimmune disorders in humans remains limited. Most research is preliminary, involving animal models or small pilot studies, and focuses largely on mechanisms rather than clinical outcomes. There is some evidence that prebiotic supplementation can reduce inflammatory markers and improve immune regulation, but robust, large-scale human trials demonstrating clear benefit in autoimmune disease patients are lacking as of 2024. Therefore, while the scientific rationale exists, the evidence base is not yet strong enough to recommend oligosaccharides as a primary treatment for autoimmune disorders.

More about Oligosaccharides
More about Autoimmune Disorders

Other ingredients used for Autoimmune Disorders

Other health conditions supported by Oligosaccharides

Products containing Oligosaccharides